Search results
Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting. Emend is used in patients aged from 6 months to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose is 125 mg orally once daily one hour before start of chemotherapy on Day 1 and 80 mg orally once daily on Days 2 and 3 in the morning.
EMEND należy przyjmować przez 3 dni w skojarzeniu z kortykosteroidem i antagonistą receptora 5-HT3. Zalecana dawka wynosi 125 mg, raz na dobę, podana doustnie na godzinę przed rozpoczęciem chemioterapii w 1. dniu oraz dawka 80 mg, raz na dobę, podana doustnie rano w 2. i 3. dniu.
EMEND is given for 3days as part of a regimen that includes a corticosteroid and a 5-HT3antagonist. The recommended dose is 125mg orally once daily one hour before start of chemotherapy on Day1 and 80mg orally once daily on Days2and3 in the morning.
EMEND® is a substance P/neurokinin 1 (NK1) receptor antagonist. EMEND for oral suspension is indicated in combination with other antiemetic agents, in patients 6 months of
The indication applied for EMEND by the Applicant is “prevention of acute and delayed nausea and vomiting associated with initial and repeated courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin, in combination with other antiemetic agents”. The proposed regimen of
SUMMARY PRODUCT INFORMATION. INDICATIONS AND CLINICAL USE. EMEND® (aprepitant), in combination with a 5-HT3 antagonist class of antiemetics and dexamethasone, is indicated for the: prevention of acute and delayed nausea and vomiting due to highly emetogenic cancer chemotherapy.
